Note: Descriptions are shown in the official language in which they were submitted.
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
1
IMPROVED PROTEIN EXPRESSION STRAINS
Field of the invention
This invention relates primarily to the development of fungal strains which
express proteins at levels substantially higher than the parental strains.
Background and prior art
io For some 20 years, desired foreign proteins have been produced in
microorganisms. However, having introduced the necessary coding
sequence and obtained expression, much still remains to be done in order
to optimise the process for commercial production. One area of interest
concerns strain improvement, that is to say finding or making strains of
the host microorganism which enable the protein to be made in higher
yields or better purity, for example.
To increase the yield, once a good expression system (eg transcription
promoter) has been devised, one might envisage trying to increase the
copy number of the coding sequence (although this will have the desired
effect only if DNA transcription was the limiting factor), or to increase the
stability of "the mRNA or to decrease the degradation of the protein.
Thus, as an example of the latter approach, yeast strains (eg pep4-3)
which are deficient in certain proteases have been used for producing
desired foreign proteins. In another approach, the number of 2 m-based
plasmids in the yeast Saccharomyces cerevisiae has been increased by
introducing a FLP gene into the genome under the control of a regulated
promoter, eg GAL. Upon switching to a growth medium containing
CA 02295190 1999-12-10
Wo 99/00504 PCT/GB98/01885
2
galactose as the sole carbon source, plasmid copy number rises (11), but
the plasmid copy number increase is uncontrolled since the GAL promoter
is not repressed by REPI /REP2. This leads to reduced growth rate and
thence clonal selection of cir derivatives of the original cir+ strain
(11,20).
We have mutated yeast strains by application of mutagens in order to
generate mutants randomly and thereby hopefully find mutant strains
which produce heterologous proteins in better yield (16,21). We have
io now characterised such a randomly-produced mutant which maintained a
higher number of copies of the plasmid expressing the desired protein and
have found that the mutation occurred in one of the genes encoding
ubiquitin-conjugating enzymes, namely UBC4. The UBC4-encoded
enzyme (and the closely related UBC5-encoded) enzyme are involved in
degrading aberrant and short lived proteins and there was no reason to
have supposed that the deletion of either of them would have enabled an
increased yield of a normal, desired, protein to have been obtained.
Several genes encoding ubiquitin conjugating enzymes (UBC) have been
implicated in the bulk protein degradation and in the stress response of
yeast. UBCI, UBC4 and UBC5 act together to mediate important
functions for cell growth and cell viability (2,3). Yeast strains with a
mutation in a single gene are viable and have similar growth rates to the
parental strains, but ubc4/ubc5 double mutants have reduced growth rates
and are sensitive to amino acid analogues, while a triple mutant is
inviable, indicating that their activities overlap. The UBC4 and UBC5
genes are closely related and the two coding DNA sequences share 77%
identical residues, while the predicted amino acid sequences of the two
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
3
proteins show 92 % identical residues (3). Because of the near identity of
the Ubc4 and Ubc5 proteins (hereafter abbreviated to Ubc4p and Ubc5p) it
has been suggested that UBC4 could complement for the loss of function
of the ubc5 mutant and vice versa (3). This would explain why the
dramatic reduction in growth rate was only observed in ubc4/ubc5 double
mutants. Pulse chase experiments have indicated that Ubc4p and Ubc5p
are responsible for the degradation of short-lived and abnormal proteins,
but that the turnover of these proteins was only reduced in strains with the
ubc4/ubc5 double mutation. It was not reduced in strains with single ubc4
io or ubc5 mutations (3). This reference, therefore, suggested that the use of
single ubc4 and ubc5 mutant fungal strains would not be beneficial.
Structurally, all known UBC genes encode a conserved domain (known as
the UBC domain) of approximately 16kDa containing the conserved
1s conjugating cysteine (1,22). Transfer of activated ubiquitin results in the
covalent attachment of the C-terminus of ubiquitin via a thioester bond to
the cysteine residue. UBC genes have been divided into different classes
(reviewed in 22). Class I UBC genes are composed almost exclusively of
the conserved UBC domain, class II and class III UBC genes have C-
20 terminal or N-terminal extension, respectively, while class IV UBC genes
have both C- and N-terminal extensions (22).
The fungal genome is composed of chromosomes, extrachromosomal
copies of chromosomal genes, eg nucleosomes, and occasionally stable
25 extrachromosomal elements. These extrachromosomal elements have
developed a benignly _ parasitic relationship with their host, where they
successfully balance the theft of cellular resource for the replication and
segregation of the element, while not compromising the fitness of the host.
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
4
General reviews of fungal extrachromosomal elements are covered by
references 5 and 6, while the DNA plasmids of the yeasts Saccharomyces
species are covered by references 7 and 8 and Kluyveromyces species are
covered by reference 9.
The 2 m plasmids of Saccharomyces species are extrachromosomal DNA
species which have evolved mechanisms to ensure their long term
autonomous survival without any associated phenotype. The 2 m plasmid
resides in the nucleus and is packaged into chromatin. The plasmid origin
io of replication acts as an autonomously replicating sequence, while other
sequences ensure the maintenance of a controlled high copy number and
allow the plasmid to partition uniformly into the daughter cells at mitosis.
The plasmid is not required for normal mitotic growth and does not
provide the host with any selective advantage since Saccharomyces species
devoid of 21im plasmid, denoted as cir , grow only slightly faster than
their 2 m plasmid containing, or cir+, parents.
The 2 m plasrnid is a double stranded circular plasmid of approximately
6,318 bp, comprising two unique regions of 2,774 and 2,346 bp separated
2o by a pair of exact inverted repeats, each 599 bp long (10). In vivo the
monomeric plasmid exists as an equal mixture of the two inversion
isomers (A and B) that form following site specific recombination between
the two inverted repeats. The 2 m plasmid has four open reading frames
known as FLP (also known as A), REPI (also known as B), REP2 (also
known as C) and RAF (also known as D). The plasmid also contains a
region, located between RAF and the origin of replication, called STB or
REP3, which is composed of a series of imperfect 62 bp repeat elements.
This element is required in cis, along with the trans acting elements,
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
REPI and REP2, to enable efficient partitioning of the plasmid between
the mother and the daughter cell.
The 2 m plasmid copy number is also indirectly under the control of
5 chromosomal genes, since it is known that 2 m plasmid copy number
does vary between different Saccharomyces cerevisiae strains and because
the chromosomal recessive mutation, known as nibl, results in clonal
lethality due to uncontrolled amplification of 2 m plasmid copy number
(39). Yeast strains carrying the nibl mutation resemble engineered yeast
i o strains where FLP gene expression is galactose induced. The involvement
of proteins of the fungal ATP-dependent ubiquitin protein degradation
pathway in the regulation of fungal plasmid copy number is not described
in the art. Nor is it disclosed that genes of the fungal ATP-dependent
ubiquitin protein degradation pathway can be manipulated to control
fungal plasmid copy number.
Although the 2 m plasmid is a very common genetic component of
Saccharomyces cerevisiae, other yeast strains are known to contain
identifiable DNA plasmids, notably the pSR1 and pSB3 plasmids (6,251
2o bp and 6,615 bp) of Zygosaccharomyces rouxii, the pSB 1 and pSB2
plasmids (6,550 bp and 5,415 bp) of Zygosaccharomyces bailii, the pSM1
plasmid (5,416) of Zygosaccharomyces fermentati and the pKD 1 plasmid
(4,757 bp) of Kluyveromyces drosophilarum (9). The most striking
feature of all these plasmids is their resemblance to the Saccharomyces
cerevisiae 2 m plasmid. Each plasmid is circular, double stranded DNA
and is composed of two approximately equally sized halves separated by
inverted repeat sequences. Each plasmid contains a single Autonomously
Replicating Sequence (ARS) close to one of the inverted repeat sequences
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
6
and three or four open reading frames, one of which encodes a
recombinase which catalyses recombination between the inverted repeats.
A Saccharomyces cerevisiae plasmid is considered to be "2 m-based" if it
contains at least one of the 24m plasmid elements (ARS, inverted repeat
sequences or 24m open reading frames), especially the ARS.
Summary of the Invention
io One aspect of the present invention provides a process of producing a
fungal cell derived product, comprising (i) providing a fungal cell having
a plasmid, the plasmid comprising a functional coding sequence for a
protein, and the fungal cell having a modified level of Ubc4p or Ubc5p
(hereinafter, generically known as Ubcp activity), and (ii) culturing the
cell to produce the fungal cell derived product.
Preferably the fungal cell derived product is a desired protein encoded by
the said coding sequence, and the said modified level of Ubcp activity is
lower than normal for the cell. This can be tested in vivo by assaying for
the rate of abnormal protein turnover (3). The level of Ubcp (Ubc4p
and/or Ubc5p) activity may be reduced to at most 50%, 40%, 30%, 20%,
10% or 1% of the wild-type level. Preferably, the cell has a minimal
Ubc4p or Ubc5p activity. The cell should not, however, have a low level
of both Ubc4p and Ubc5p, since its growth rate will generally be too low
to be useful.
The reduction in Ubcp activity can be achieved in any one of a variety of
ways. Firstly the cell can produce a compound which interferes with the
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
7
binding of the UBC-encoded product to its receptor. Hence, a construct
may be provided in the cell to express a polypeptide which competes for
the binding of Ubc4p or Ubc5p to its target. This will facilitate a
reduction in the effective Ubc4p or Ubc5p activity. This may be done by
over-expressing the UBC domain encoded by UBC4 or UBC5 described
above. It will be important to ensure that the over-expressed UBC domain
encoded by UBC4 or UBCS does not have any intrinsic Ubc4p or Ubc5p
activity of its own, since this might actually contribute to the overall
Ubc4p or Ubc5p activity. This may be achieved, by site directed
io mutagenesis, by removing or replacing (for example with an alanine) the
cysteine which acts as the acceptor site for the ubiquitin within the UBC
domain of UBC4 (or 5) or other conserved amino acids within the UBC
domain. Over expression of the inactive UBC domain of UBC4 (or 5)
may be achieved from its own endogenous promoter, or from any other
convenient promoter.The construct may be integrated into the
chromosome or episomal.
Alternatively, in order to achieve a reduced level of Ubcp activity, the
endogenous UBC gene may be modified such that substantially no protein
is produced therefrom or such that any protein produced therefrom has a
reduced level of Ubc4p or Ubc5p activity. Thus, for example, the UBC
gene may be deleted (either in a regulatory region or in the coding region
or both) such that no polypeptide is produced or a mutant (defective)
polypeptide product is produced. (By "regulatory region", we include
' 25 parts of the genome acting on the UBC gene indirectly, for example a
gene producing a UBC gene activator.) Deletion of all or part of the UBC
open reading frame (14) is preferred, as this will reduce or abolish Ubcp
activity and generate a non-reverting mutant fungal strain. Alternatively,
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
8
the activity can be reduced or abolished by classical mutagenesis
procedures, whereby the DNA sequence of the UBC gene is mutated in
such a way as to produce point mutations or deletions which modify
and/or disrupt the normal amino acid sequence of the Ubcp. If a mutant
Ubcp polypeptide is produced, it may be unstable (ie be subject to
increased protein turnover relative to the native protein); or unable to
conjugate ubiquitin,or unable to deliver bound ubiquitin to its substrate.
For example, the UBC gene may be modified such that the ubiquitin-
io accepting cysteine in any protein produced therefrom is absent or of
reduced ubiquitin-accepting activity, for example due to alterations in the
amino acid residues surrounding or otherwise interacting with the
cysteine, as noted above in the context of producing competitive (but
inactive) polypeptide. Alternatively, the UBC gene may be modified such
that the capacity of any mutant protein produced therefrom is unable to
interact with or has reduced affinity for the El ubiquitin donor (product of
the UBAI or UBA2 genes). Alternatively, the UBC gene may be modified
such that the capacity of any mutant protein produced therefrom to interact
with the fmal ubiquitin acceptor and/or the Ubiquitin ligase (E3) enzyme
is absent or reduced. Specifically, mutations (deletion, insertions or
substitutions) within the first 21 amino acids of the primary sequence and
the first a helix (residues 3-13) of Ubc4p and Ubc5p (29) are preferred as
the latter have been implicated in binding of Ubc2p, a related protein, to
the ubiquitin protein ligase Ubrlp (33). Especially preferred are
mutations affecting the glutamic acid at position 10 (Glu-10) within the
primary sequence of Ubc4p and Ubc5p, particularly replacement by lysine
(GlulOLys) or arginine (GlulOArg).
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
9
Alternatively a different promoter may be used to control expression of
the UBC gene; such a promoter may be regulatable. For example, it may
be inducible, as are promoters of the galactose utilisation pathway, or
derepressed by the removal of an inhibitor, as are promoters of the acid
phosphatase group.
Site-directed mutagenesis or other known techniques can be employed to
create single or multiple mutations, such as replacements, insertions,
deletions, and transpositions, as described in reference 23. Suitable
f o mutations include chain termination mutations (clearly stop codons
introduced near the 3' end might have insufficient effect on the gene
product to be of benefit; the person skilled in the art will readily be able
to
create a mutation in, say, the 5' three quarters of the coding sequence),
point mutations that alter the reading frame, small to large deletions of
coding sequence, mutations in the promoter or terminator that affect gene
expression and mutations that de-stabilize the mRNA. Specific mutations
can be introduced by an extension of the gene disruption technique known
as gene transplacement (24).
2o Generally one uses a selectable marker to disrupt a gene sequence, but this
need not be the case, particularly if one can detect the disruption event
phenotypically. In many instances the insertion of the intervening
sequence will be such that a stop codon is present in frame with the UBC
sequence and the inserted coding sequence is not translated. Alternatively
the inserted sequence may be in a different reading frame to UBC.
A third principal way to achieve a reduction of Ubcp activity is for the cell
to produce UBC antisense mRNA. This may be achieved in conventional
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
ways, by including in the cell an expression construct for an appropriate
sequence. UBC antisense mRNA may be produced from a constitutive or
regulated promoter svstem (eg promoters of the galactose catabolic
pathway), thereby facilitating a reduction in translatable UBC mRNA.
5 Use of the regulated UBC antisense mRNA also allows for control of the
ubiquitin-dependent protein degradation pathway by the addition or
removal of the activator.
Fungal cells useful in the methods of the invention include the genera
io Pichia, Saccharomyces, Zygosaccharomyces, Kluyveromyces, Candida,
Torulopsis, Hansenula (now reclassified as Pichia), Schizosaccharomyces,
Citeromyces, Pachysolen, Debaromyces, Aspergillus, Metschunikowia,
Rhodoporidum, Leucosporidum, Botryoascus, Endomycopis, Trichoderma,
Cephalosporium, Humicola, Mucor, Neurospora and the like. Preferred
genera are Pichia, Saccharomyces, Zygosaccharomyces and
Kluyveromyces. Examples of Saccharomyces sp. are Saccharomyces
cerevisiae, Saccharomyces italicus, Sacclzaromyces diastaticus and
Zygosaccharonzyces rouxii. Examples of Kluyveromyces sp. are
Kluyveromyces.fragilis and Kluyveromyces lactis. Examples of Hansenula
sp. are Hansenula polymorpha (now Pichia angusta), Hansenula anomala
(now Pichia anomala) and Pichia capsulata. An example of a Pichia sp.
is Pichia pastoris. Examples of Aspergillus sp. are Aspergillus niger and
Aspergillus nidulans. Yarrowia lipolytica is an example of a suitable
Yarrowia species.
Preferred are yeast strains, and of these Saccharomyces cerevisiae is the
particularly preferred host. The yeast strains used can be any haploid or
diploid strain of Saccharomyces cerevisiae, but in the case of diploid
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
11
strains it is preferred that the activity of the Ubcp enzyme from both
copies of the UBC gene is reduced or abolished.
A number of species have been shown to have homologues of
s Saccharomyces cerevisiae UBC4 and UBC5 genes. UBC4 and UBC5
homologues have been described in Homo sapiens (34) , Drosophila
melanogaster (35), Caenorhabditis elegans (36), Arabidopsis thaliana
(37), Schizosaccharomyces pombe and Candida albicans (38). The
Drosophila melanogaster and Caenorhabditis elegans homologues, UbcDl
io and ubc-2, respectively, have also been shown to have Ubcp activity. It
can be seen that a homologue need not be termed UBC4 or UBC5;
equally, a gene which is called UBC4 or UBC5 need not be a homologue.
Of the known UBC4/UBC5 homologues in the literature, the similarity of
15 the various proteins can be calculated by aligning the primary amino acid
sequences. A suitable program is the Megalign Program, Lasergene,
DNASTAR Inc, 1228 South Park Street, Madison, Wisconsin 53715,
USA. Using such a program the calculated percentage similarity ranges
from 75 .7 % to 97.3. These values are very high and reflect the highly
20 conserved nature of the Ubc proteins. The highly conserved cysteine
residue in the active site occurs at position 193 in the consensus sequence.
Of the other Ubc proteins, the calculated percentage similarity between
them and to Saccharomyces cerevisiae Ubc4p and Ubc5p ranged from
25 24.2 % to 63.5 %. Proteins homologous to the Saccharomyces cerevisiae
Ubc4p and Ubc5p can therefore be defined as any Class I (as defined by
Jentsch, 1992, reference 22) ubiquitin conjugating enzyme, which
possesses 66.7% or greater primary amino acid sequence similarity to
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
12
Saccharomyces cerevisiae Ubc4p or Ubc5p, as defined by the Megalign
program. A gene is deemed to be homologous to S. cerevisiae UBC4 or
UBC5 if it encodes such an enzyme.
A number of species have also been shown to possess Ubcp activity. As
stated previously ubc4/ubc5 double mutants of Saccharomyces cerevisiae
have increased doubling time, reduced resistance to amino acid analogues
and reduced resistance to heat shock. It is known that the Drosophila
UBC1 protein, encoded by the UbcDl gene, which is 79.6% and 80.3%
i o similar to Saccharanyces cerevisiae Ubc4p and Ubc5p respectively, can
reverse the phenotypes of a yeast with no Ubc4p or Ubc5p activity when
placed downstream of the UBC4 promoter (35). Similarly it is also known
that the Caenorhabditis protein ubc-2, encoded by the ubc-2 gene, which
is 78.2 % and 78.9% similar to Saccharomyces cerevisiae Ubc4p and
Ubc5p respectively, has the same properties (36). This is therefore a
functional test of whether a protein from an unknown source has Ubc4p or
Ubc5p activity. It can also be seen that, for the examples of doubling time
and survival rate after 24hrs at 38 C, the single ubc4 or ubc5 mutant
strains described by Seufert and Jentsch (3,36) have similar characteristics
to the wild-type strain. The Ubcp activity of an unknown Ubc protein, or
a mutant form of a known Ubc protein, relative to the natural
Saccharomyces cerevisiae Ubc4p or Ubc5p, can be determined by its
relative ability to return the doubling time or survival rate after 24hrs at
38 C (as described in references 3 or 36), of a double ubc4/ubc5 mutant
strain to normal for a wild type or single ubc4 or ubc5 mutant
Saccharomyces cerevisiae strain once the unknown or mutant Ubc protein
has been integrated into the Saccharoinyces cerevisiae genome under the
control of the endogenous UBC4 or UBC5 promoter, preferably as a
CA 02295190 1999-12-10
WO "/00504 PCT/GB98/01885
13
single copy integration at the endogenous UBC4 or UBCS locus by
procedures already described in the literature (36).
In a preferred aspect of the invention, the level of Ubc4p or Ubc5p
activity is reduced. This has been found to increase the copy number of
an expression plasmid in the cell, and to cause an increased level of
expression of a desired protein expressed from the plasmid. Conversely,
increasing the level of Ubc4p or Ubc5p activity will reduce the level of
expression of the protein, which may be desirable in some circumstances,
io for example where the plasmid-encoded protein inhibits production of the
desired protein.
The term "desired protein" is used herein in the normal sense to mean any
protein (or other polypeptide) which is desired in a given process at a
higher level than the one at which the fungal cell would, without human
intervention, produce it. The desired protein may be endogenous to the
species in question, for example it may be an enzyme which is normally
produced by the host cell. Usually, however, the protein is heterologous
to the host cell. The protein may perform its required task in the host cell
or host cell culture without being extracted. Usually, however, the
protein is extracted from the cell culture and purified to some extent for
use elsewhere. The protein may be a viral, microbial, fungal, plant or
animal protein, for example a mammalian protein. Preferably, it is a
human protein, for example albumin, immunoglobulin or a fragment
thereof (such as an Fab fragment or single chain antibody), (haemo-
)globin, blood clotting factors (such as factors II, VII, VIII, IX),
interferons, interleukins, a,-antitrypsin, insulin, calcitonin, cell surface
receptors, fibronectin, pro-urokinase, (pre-pro)-chymosin, antigens for
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
14
vaccines, t-PA, tumour necrosis factor, erythropoietin, G-CSF, GM-CSF
growth hormone, platelet-derived endothelial cell growth factor, and
enzymes generally, such as glucose oxidase and superoxide dismutase.
The protein is, of course, not Ubc4p or Ubc5p itself, nor a fusion of either
Ubc4p or Ubc5p in which the Ubc4p or Ubc5p performs its natural
function.
The desired protein, if it is to be purified from the fungal cell culture, may
be obtained by any technique suited to that protein. For example, albumin
io may be purified from a Saccharoinyces, Kluyveromyces or Pichia cell
culture according to the techniques disclosed in W096/37515, EP-625 202
or EP-464 590, respectively.
Our work has principally involved human albumin, although there is no
reason to suppose that the process of the invention is applicable only to
this protein, especially since the invention has also been shown to be
advantageous in the expression of human haemoglobin.
The term "human albumin" is used herein to denote material which is
indistinguishable from human serum albumin or which is a variant or
fragment thereof. By "variant" we include insertions, deletions and
substitutions, either conservative or non-conservative, where such changes
do not substantially alter the oncotic, useful ligand-binding or
immunogenic properties or albumin. For example we include naturally-
occurring polymorphic variants of human albumin or human albumin
analogues disclosed in EP-A-322 094. Generally, variants or fragments of
human albumin will have at least 50 %(preferably at least 80%, 90% or
95 %) of human serum albumin's ligand binding activity (for example
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
bilirubin-binding) and at least 50 % (preferably at least 80 %, 90 % or 95 %)
of human serum albumin's oncotic activity, weight for weight.
The desired protein coding region is preferably contained within a hybrid
5 plasmid comprising a promoter sequence, a DNA coding sequence which
is under the transcriptional control of the promoter, a leader sequence
directing the secretion of the protein and a DNA sequence containing a
eukaryotic transcription termination signal, which plasmid is then
maintained as an extrachromosomal DNA sequence or is integrated into
io one or more chromosomes of the host organism.
Suitable promoters for the expression of the protein include those
associated with the phosphoglycerate kinase (PGKI ) gene, galactokinase
(GALI) and uridine diphosphoglucose 4-epimerase (GAL1O) genes, iso-1-
15 cytochrome c(CYC1), acid phosphatase (PHOS), alcohol dehydrogenase
genes (ADHI and ADH2) and MFa-1. The preferred promoters are the
glycerol-3-phosphate dehydrogenase (GPD1), described in EP 424 117,
and the protease B(PRBl ) promoter, described in EP-431 880 B 1.
Suitable transcription termination sequences can be the 3' flanking
sequence of the eukaryotic gene which contains proper signals for
transcription termination and polyadenylation in the fungal host, or those
of the gene naturally linked to the expression control sequence, or those
associated with the phosphoglycerate kinase (PGKI) or the iso-1-
cytochrome c(CYCI) gene. The preferred transcription termination
sequence is from the alcohol dehydrogenase gene (ADHl ).
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
16
Suitable secretory leader sequences are, for example, the natural human
serum albumin leader sequence, the leader sequence from the
Saccharomyces cerevisiae MFa-1 leader sequence, the Kluyveromyces
lactis killer toxin leader, a fusion between the natural human serum
albumin leader and the Saccharomyces cerevisiae MFa-1 leader sequence,
or a fusion between the Kluyveromyces lactis killer toxin leader and the
Saccharomyces cerevisiae MFa-1 leader sequence, or conservatively
modified variations of these sequences, as described in WO 90/01063.
io Hybrid plasmids may also be used which, apart from the expression
control sequence, the heterologous gene sequence and the transcription
termination sequence, contain additional sequences which are non-essential
or less important for the function of the promoter, ie for the expression of
the desired polypeptide, but which perform important functions in, for
example, the propagation of the cells transformed with the said hybrid
plasmids. The additional DNA sequences may be derived from
prokaryotic and/or eukaryotic cells and may include chromosomal and/or
extra-chromosomal DNA sequences. For example, the additional DNA
sequences may stem from (or consist of) plasmid DNA, such as bacterial,
yeast or higher eukaryotic chromosomal DNA. Preferred hybrid plasmids
contain additional DNA sequences derived from bacterial plasmids,
especially Escherichia coli plasmid pBR322 or related plasmids,
bacteriophage, yeast 2 m plasmid, and/or yeast chromosomal DNA.
In the preferred hybrid plasmids for the expression of the heterologous
polypeptide, the additional DNA sequences carry a yeast replication origin
and a selective genetic marker for yeast. Hybrid plasmids containing a
yeast replication origin, eg an autonomously replicating segment (ARS),
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
17
are extrachromosomally maintained with the yeast cells after
transformation and are autonomously replicated upon mitosis. Hybrid
plasmids containing sequences homologous to the yeast 2 m plasmid DNA
can be as well. These hybrid plasmids may be integrated by
recombination into yeast 2 m plasmids already present within the cell or
may replicate autonomously. The integration vectors of EP-A-251 744 or
the "disintegration" vectors of EP-A-286 424 may be used.
Advantageously, the additional DNA sequences which are present in the
io hybrid plasmids also include a replication origin and a selective marker
for
the bacterial host, especially Escherichia coli, and a selectable marker for
the final fungal host. There are useful features which are associated with
the presence of an Escherichia coli replication origin and an Escherichia
coli marker in a yeast hybrid plasmid. Firstly, large amounts of hybrid
plasmid DNA can be obtained by growth and amplification in Escherichia
coli and, secondly, the construction of hybrid plasmids is conveniently
done in Escherichia coli making use of the whole repertoire of cloning
technology based on Escherichia coli. Escherichia coli plasmids, such as
pBR322 and the like, contain both Escherichia coli replication original and
2o Escherichia coli genetic markers conferring resistance to antibiotics, for
example tetracycline and ampicillin, and are advantageously employed as
part of the yeast hybrid vectors. The selective fungal marker may be any
gene which facilitates the selection of transformants due to the phenotypic
expression of the marker. Suitable markers are particularly those
expressing antibiotic resistance or, as in the case of auxotrophic yeast
mutants, genes which complement host lesions. Corresponding genes
confer, for example, resistance to the antibiotic cycloheximide or provide
CA 02295190 2006-02-24
WO 99/00504 PCT/cB98/01885
18
for prototrophy in an auxotrophic yeast mutant, for example the URA1,
URA3, LEU2, HIS3, HIS4, TRP5, TRPI and LYS2 genes.
It has been demonstrated that fungal cells of the genera Pichia,
s Saccharomyces, Kluyveromyces, Yarrowia and Hansenula can be
transformed by enzymatic digestion of the cell walls to give spheroplasts;
the spheroplasts are then mixed with the transforming DNA and incubated
in the presence of calcium ions and polyethylene glycol, then transformed
spheroplasts are regenerated in regeneration medium. The regeneration
io medium is prepared in such a way as to allow regeneration and selection
of the transformed cells at the same time.
Since the yeast genes coding for enzymes of nucleic acid or amino acid
biosynthetic pathways are generally used as selection markers, the
15 regeneration is preferably performed in yeast minimal medium. Methods
for the transformation of Saccharomyces cerevisiae are taught generally in
EP 251 744, EP 258 067, WO 90/01063 and by Hinnen et al (4).
2o Hence, in its broadest aspect, the invention provides the use of a means to
vary UBC4 or UBC5 function in a fungal cell to control the copy number
of a plasmid in that cell.
Preferred non-limiting embodiments of the invention will now be
25 described by way of example and with reference to the accompanying
drawings, in which:
Figure 1 is a plasmid map of pDB2277;
CA 02295190 2006-02-24
WO 99/00504 I'CT/GB98/01885
19
Figure 2 is photograph of a rocket inimunoelectrophoresis gel
showing the inereased rl-IA productivity of ubc5 disrupted yeast. Strains
were as follows: Sainple 1, DS569 ura3 [pAYE329/YCplae33]; Samples
2-17, DS569 ura3 [pAYE329/pDB2276] transformants 1-16; Samples 18-
s 34 , DS1101 ura3 [pAYE329/pDB2276] transformants 1-16; Samples 35-
39 I1SA stattdards 100, 75, 50, 30, and 20 g/mL HSA;
Figure 3 is the genomic DNA sequence of the yeast Saccharomyces
cerevisiae gene UBC4; the 2.066 kb sequence extends from the Pstl site
0.95 kb upstream of the start of the UBC4 open reading frame to the Pstl
-o site 0.58 kb downstream of the translation stop codon; (SEQ ID NO :19 )
Figure 4 is a plasmid map of pAYE399;
Figure 5 is a plasmid map of pAYE400;
Figure 6 is a plasmid map of pUBT 1;
Figure 7 is a plasmid map of pUBT2;
15 Figure 8 is a plasmid map of pHbD2-1;
Figure 9 is a plasmid map of pAYE792;
Figure 10 is a plasmid map of pBST +;
Figure 11 is a plasmid map of pDB2258;
Figure 12 is a plasmid map of pDB2259;
20 Figure 13 is a plasmid map of pDB2260;
Figure 14 is a plasmid map of pDB2261;
Figure 15 is the genomic DNA sequence of the Saccharontyces
cerevisiae UBC5 gene; the 1.2 kb sequence extends from the Bg1II site
0.55 kb upstream of the start of the UBC5 open reading frame to the Bcll
25 site 0.12 kb downstream of the translation stop codon: (SEQ ID NO : 2 0)
Figure 16 is a plasmid map of pDB2262;
Figure 17 is a plasmid map of pDB2264;
Figure 18 is a plasmid map of pDB2275; and
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
Figure 19 is a plasmid map of pDB2276.
Detailed description of the invention
5 All standard recombinant DNA procedures are as described in reference
13 unless otherwise stated.
Example 1: Disruption of the Saccharomyces cerevisiae UBC4 gene
io The Saccharonzyces cerevisiae UBC4 gene is located on chromosome II.
The DNA sequence of the UBC4 gene is shown in Figure 3.
The UBC4 gene was mutated by the process of gene disruption (14) which
deleted the entire UBC4 open reading frame, thereby preventing
15 production of active Ubc4 protein. This was achieved by first amplifying
by PCR a suitable marker gene (URA3) with mutagenic single stranded
DNA primers which modified the 5' and 3' ends of the URA3 gene so as
to include DNA sequences identical to regions 5' and 3' to the UBC4 open
reading frame and then transforming a ura3 auxotrophic yeast strain to
20 uracil prototrophy.
Two single stranded oligonucleotide primers (UBC4URA 1 and
UBC4URA2) suitable for PCR amplification of the 5' and 3' ends of the
URA3 gene, incorporating UBC4 sequences at the extremes, were
synthesised using an ABI 380B DNA Synthesiser.
CA 02295190 2006-02-24
WO 99/00504 PCT/GI398/01885
21
UI3C4URA 1 5"I"I"rCATCGTC CAATCCCATA TAAATCTTGC
TTCTCTTTTT CAGCTGAGTA AGCTTTTCAA
TTC ATCTTTT-3' (SEQ ID NO :1)
UBC4URA2 5'-TCTTATTTTT CATCTTAATA AATAATCCAG
AGAATAAATC TATCCTGAAA AGCTTTTTCT
TTCCAATTTT-3' (SEQ ID NO : 2)
PCR reactions were performed to amplify the URA3 gene from the
io plasmid YEp24 (15). Conditions were as follows: 1 g/mL plasmid
YEp24 DNA, 2 M of each primer, denature at 94 C for 30 seconds,
anneal to 45 C for 40 seconds, extend at 72 C for 120 seconds for 20
cycles, followed by a 72 C soak for 600 seconds, followed by a 4 C soak,
using a Perkin-Elmer-Cetus Thermal Cycler and a Perkin-Elmer-Cetus
1s PCR kit employing AmpliTaqTM Fhermal Stable DNA Polymerase, total
reaction volume 50 L, accordirig to the manufacturer's instructions.
Alternative conditions were, 2ng/mL plasmid YEp24 DNA, 0.1 M of
each primer, denature at 949C for 30 seconds, anneal to 55 C for 40
seconds, extend at 72 C for 120 seconds for 30 cycles, followed by a 72 C
20 soak for 600 seconds, followed by a 4 C soak, using a Perkin-Elmer-Cetus
Thermal Cycler and a Perkin-Elmer-Cetus PCR kit employing AmpliTaqrm
Thermal Stable DNA Polymerase, total reaction volume 50 L, according
to the manufacturer's instructions. The product, 5'-UBC4-UR,43-UBC4-
3', was analysed by gel electrophoresis and was found to be of the
25 expected size, approximately 1.2kb. The amplified PCR products were
purified using a Promega Wizard PCR DNA purification kit according to
the manufacturer's instructions.
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
22
The Sacclzaromvices cerevisiae strain DS569 cir (16) was transformed to
leucine prototrophy with the recombinant human albumin (rHA) secretion
plasmid pAYE329 (19). The promoter sequence in this plasmid
corresponds to that of the Saccharomyces cerevisiae NAD-linked glycerol-
3-phosphate dehydrogenase (GPDI ) gene, rather than the FAD-linked
glycerol-3-phosphate dehydrogenase (GUT2) gene as originally described
(19).
The ura3 auxotrophic derivative of the Saccharomyces cerevisiae strain
i o DS569 [pAYE329] was created by mutating the URA3 gene by the process
of gene disruption (14) which deleted part of the URA3 coding sequence,
thereby preventing the production of active Ura3 protein. The plasmid
YEp24 (15) was digested to completion with HindIII and the products
resolved by gel electrophoresis. The 1.17kb HindlIl URA3 gene fragment
was isolated and ligated into the unique HindIII site of pACYC184 (17) to
create plasmid pAYE399, Figure 4. Plasmid pAYE339 was digested to
completion with Pst1 and partially digested with Nco1, the products were
resolved by gel electrophoresis and the 5.41kb Ncol-Pstl DNA fragment
lacking the central part of the URA3 gene was isolated, blunt-end filled
with the Klenow fragment of DNA Polymerase and religated. The
resultant plasmid pAYE400, Figure 5, possesses a deletion within the
URA3 open reading frame and an Ncol site at the deletion site. The
deletion derivative of URA3 gene (DURA3) was isolated as a 0.94kb
HindIII fragment from plasmid pAYE400. A ura3 auxotrophic mutant of
DS569 [pAYE329] was created by transforming DS569 [pAYE329] with
the AURA3 0.94kb HiizdIII fragment and selecting for Ura yeast by
resistance to 5-fluoro-orotic acid (18). Colonies able to grow on this
medium were purified, tested to verify that they were unable to grow in
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
23
the absence of uracil supplementation and that the defect could be
complemented by introduction of the URA3 gene by transformation.
One such strain, DS569 ura3 [pAYE329], was transformed to uracil
s prototrophy with the 5'-UBC4-URA3-UBC4-3' PCR product. A Southern
blot of digested genomic DNA of a number transformants was probed with
the UBC4 gene as a 2.07kb Pstl DNA fragment and confirmed the
disruption of the UBC4 gene. The new strain was designated UB05
[pAYE329].
These methods are equally applicable to the disruption of UBC4 in any
haploid Saccharomyces cerevisiae strain. If the desired host already
carries a ura3 auxotrophic mutation, then disruption of UBC4 can be
performed with the 5'-UBC4-URA3-UBC4-3' PCR product described
above. If the desired haploid host does not carry a ura3 auxotrophic
mutation, then disruption of UBC4 can be performed once the strain has
been made ura3 by transformation with the DURA3 0.94kb HindIII
fragment from pAYE400 and selecting for Ura- yeast by resistance to 5-
fluoro-orotic acid as described above. In the case of a diploid host it is
2o necessary to disrupt both UBC4 genes. This can be achieved by
disrupting the UBC4 gene in each of the two parental haploid strains first
before diploidisation.
Example 2: Disruption of the Saccharomyces cerevisiae UBC4 gene
enhanced the production of recombinant human albumin.
The rHA productivity of the yeast strain DS569 [pAYE329] (which does
not have a UBC4 disruption) and two independent isolates of UB05
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
24
[pAYE329], called UB05-1 [pAYE329] and UBO5-6 [pAYE329] (both of
which do have a UBC4 disruption) was assessed in lOmL shake flask
culture. Yeast were inoculated into YNB (Difco) minimal medium,
buffered with sodium phosphate/citrate pH 6.0 and containing 2% w/v
glucose, and incubated at 30 C, 200 rpm for 3 days. The rHA
productivity was estimated by rocket immunoelectrophoresis against HSA
standards (25-150 g/mL). The rHA productivity of DS569 [pAYE329]
under these conditions was calculated to be 45mg/L, while the rHA
productivity of the two UB05 [pAYE329] isolates measured under
io identical conditions was calculated to be 77 and 75 mg/L, respectively.
Example 3: Disruption of the Saccharoinyces cerevisiae UBC4 gene
increases hybrid 2 m plasmid copy number.
The plasmid copy number of the hybrid 2 m plasmid of the yeast strains
DS569 [pAYE329] and two independent isolates of UB05 [pAYE329],
called UB05-1 [pAYE329] and UB05-6 [pAYE329], was assessed in
lOOmL shake flask culture. Yeast were inoculated into YNB minimal
medium, buffered with sodium phosphate/citrate pH 6.0 and containing
2o 2% w/v glucose, and incubated at 30 C, 200 rpm for sufficient time,
usually 1 to 2 days, to allow the culture density to exceed 5 AU/mL,
equivalent to mid-logarithmic growth phase. Total genomic DNA was
extracted by glass disruption of the yeast cells, followed by solvent
extraction, dialysis and ethanol precipitation. The total genomic DNA
was digested to completion with HindIII and the products analysed by gel
electrophoresis. The ethidium bromide staining of the plasmid specific
DNA bands increased relative to the ethidium bromide staining of the
ribosomal DNA (rDNA) bands, indicating that the plasmid copy number
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
of the hybrid 2 m plasmid had increased. Quantitation of the hybrid 2 m
plasmid copy number relative to the copy number of the rDNA was
performed by Southern blot analysis with a joint rDNA/HSA cDNA
probe. This showed that the plasmid copy number of the hybrid 2 m
5 plasmid pAYE329 increased from 48.9 9.2 copies per haploid genome
in DS569 [pAYE329j to 83.1 12.5 and 116.8 29.0 copies per haploid
genome in UB05-1 [pAYE329] and UB05-6 [pAYE329], respectively.
Example 4: Antisense UBC4 mRNA expression.
One way to disrupt expression of the UBC4 gene is to arrange for
expression of an antisense polynucleotide.
The antisense transcript can be expressed from a copy, or copies, of the
antisense expression cassette which have been integrated into the
chromosome(s), or it can be expressed from a low plasmid copy number
vector, eg a centromeric vector like YCp50 (25) or YCplac 1111,
YCplac33, YCplac22 (26) or plasmids p413 through to p416 containing
the GALl, GALL or GALS promoters (27). The antisense transcript can
2o also be expressed from a high plasmid copy number vector like pJDB207
(12), YEp13 or YEp24 (15). All of these expression plasmids or
integrating cassettes require a yeast selectable marker eg URA3, HIS3 or
TRPl to facilitate selection during transformation of yeast containing the
appropriate auxotrophic marker(s).
The promoter used to drive the expression of the antisense UBC4 or anti-
sense UBC5, may be the native promoter, or a related promoter. This has
the advantage of promoting expression of the antisense transcript at the
III
CA 02295190 2000-06-27
WO 99/00504 PCT/GB98/01885
26
same time as the appearance of the sense transcript. In an especially
preferred embodiment, the antisense expression cassette is provided on a
high plasmid copy number plasmid to ensure an excess of the antisense
transcript over the sense transcript. Alternative promoters include strong
constitutive promoters such as the glycolytic promoters, eg PGKI, PYK1,
TDH2/TDH3 and ENO1 /ENO2. Use of strong regulated promoters will
have the advantage that plasmid copy number can be regulated at the will
of the operator. Examples of such promoters are the GALI, GALL and
GALS promoters (Mumberg et al, 27). These galactose-induced
io promoters have been incorporated into both high and low plasmid copy
number vectors, separated from the CYCI terminator by a multiple
cloning site. The example described below utilises a plasmid called p426
GAL] (Mumberg et al, 27). The antisense UBC4 transcript can be
effective in inactivating UBC4 sense transcript only if the host fungal
strain contains a proficient UBC4 gene. However, expression of a UBC4
antisense transcript in a ubc4 fungal strain may be beneficial in mopping
up other UBC4-1ike transcripts, so this is an option as well.
Two single stranded oligonucleotide primers (UBC43 and UBC44) suitable
for PCR amplification of the UBC4 open reading frame were synthesised
using an ABI 380B DNA Synthesiser.
UBC43 5'-ATAAACAAGC TTCCAAAAAA ACATGATTTC ACT
GACTATA GAGTACATAC-3' (SEQ ID No : 3)
UBC44 5'-GTAAGGACTT AAGCTTTATA CAGCGTATTT CT
TTGTCCAT TCTCTGGCTG TAGC-3' (SEQ ID No : 4)
CA 02295190 2006-02-24
WO 99/00504 PCr/GB98/01885
27
PCR reactions were performed to amplify the UBC4 gene from genomic
DNA prepared from the yeast strain S288C. Conditions were as follows:
glmL S288C genomic DNA, 2 M of each prinier, denature at 94 C for
30 seconds, anneal to 45 C for 40 seconds, extend at 72 C for 120 seconds
s for 35 cycles, followed by a 72 C soak for 600 seconds, followed by a 4 C
soak, using a Perkin-Elmer-Cetus Thermal Cycler and a Perkin-Elmer,
Cetus PCR kit employing AmptiTaqTM Thermal Stable DNA Polymerase,
total reaction volume 50pL, according to the manufacturer's instructions.
The product, 5'-(HindIIl)-UBC4-(HiiidIII)-3'; was analysed by gel
io electrophoresis and was found to be of the expected size, approximately
0.58kb. The amplified PCR products were purified using a Promega
Wizard PCR DNA purification kit according to the manufacturer's
instructions. Use of these two primers, UBC43 and UBC44, introduced
HindIIl sites 5' and 3' to the UBC4 open reading frame.
The purified PCR product, 5'-(HindIIl)-UBC4-(HindIII)-3', was digested
to completion with HindIIl, and ligated into the unique HindIIl site
situated between the GALI promoter and the CYCI terminator of plasmid
p426GALI (Mumberg et at, 27) generating two plasmids pUBTI and
pUBT2 (Figures 6 and 7). Plasmid pUBTI contained the UBC4 open
reading frame so orientated as to produce an antisense UBC4 transcript
from the GALI promoter, while plasmid pUBT2 contained the UBC4 open
reading frame so orientated as to produce a sense UBC4 transcript from
the GALI promoter.
Yeast strains deficient in uracil biosynthesis due to the presence of a non-
functional ura3 gene, such as DS569 ura3 [pAYE3291 (Example 1), were
transformed to uracil prototrophy with plasmid pUBT1. UBC4 antisense
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
28
transcript production was induced by switching from a yeast growth
medium containing glucose as the sole carbon source to a medium
containing galactose as the sole carbon source. Conversely, UBC4 anti-
sense transcript production was repressed by switching from a yeast
growth medium containing galactose as the sole carbon source to a
medium containing glucose as the sole carbon source.
Example 5: Sense UBC4 mRNA expression from the GALI promoter
io Plasmid pUBT2 (Figure 7) allows for the over-expression of the UBC4
transcript. In a ubc4 deficient fungal strain transformed with plasmid
pUBT2, when the carbon source is switched from glucose to galactose,
UBC4 mRNA expression will be increased and will force plasmid copy
number down. This is yet another way to facilitate control over plasmid
copy number by switching between repressing and activating carbon
sources. Again this can be done in either a ubc4 or UBC4 background.
Yeast strains deficient in uracil biosynthesis due to the presence of a non-
functional ura3 gene, such as DS569 ura3 [pAYE329] (16) or a ura3
2o derivative of UB05 [pAYE329] (Example 1), were transformed to uracil
prototrophy with plasmid pUBT2. UBC4 sense transcript production was
induced by switching from a yeast growth medium containing glucose as
the sole carbon source to a medium containing galactose as the sole carbon
source. Conversely, UBC4 sense transcript production from pUBT2 was
repressed by switching from yeast growth medium containing galactose as
the sole carbon source to a medium containing glucose as the sole carbon
source.
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
29
Example 6: Disruption of the Saccharomyces cerevisiae UBC4 genes
enhances the production of other recombinant human
proteins.
Elimination of the ubc4 gene will increase the expression of other
heterologous proteins. This was exemplified by analysing the expression
level of recombinant human haemoglobin in DS569 and DS 1101
(described later in Example 7) which possesses a mutation within the
UBC4 open reading frame. The human haemoglobin expression plasmid,
io called pHbD2-1 (Figure 8), was based on the whole 2 m disintegration
vector pSAC35 (16). Transcription of the human a-globin chain was
directed by the GPDl promoter (19) and terminated by the PGKI
terminator. Transcription of the human P-globin chain was directed from
the PRB1 promoter and terminated by the ADHl terminator (16).
The rHb productivity of the yeast strains DS569 and DS 1101 transformed
to leucine prototrophy with pHbD2-1 was assessed in lOmL shake flask
culture. Yeast were inoculated into YNB minimal medium, buffered with
sodium phosphate/citrate pH 6.0 and containing 2% (w/v) glucose, and
incubated at 30 C, 200 rpm for 3 days. The rHb productivity in yeast
soluble cell extracts was quantitated by a spectrophotometric assay from
the height of the Soret peak in a second derivative spectrum, by
comparison with standard HbA of known concentration (28). Total
soluble protein concentration was quantitated by Coomassie Protein Assay
Reagent, according to the Manufacturer's Instructions (Pierce). The
expression level of soluble rHb in DS569 [pHbD2-11 was calculated to be
equivalent to 0.4% (w/v) total soluble protein. The expression level of
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
soluble rHb increased to 0.8% (w/v) in the strain DS1101 [pHbD2-1]
carrying the ubc4 deletion.
Example 7: Mutation of the Saccharomyces cerevisiae UBC4 gene
5
As described above, the original mutation was produced by random
chemical mutagenesis. The starting strain for this process was DS569
[pAYE329] (16). DS569 [pAYE329] was subjected to chemical
mutagenesis by N-methyl-N'-nitro-N-nitrosoguanidine (NTG) and
io potential rHA over-expressing mutant strains selected by a plate screening
procedure described in EP431880. One such mutant strain was called
DS1101 [pAYE329]. Analysis of the rHA productivity of DS569
[pAYE329] and DS 1101 [pAYE329] was performed in lOmL shake flask
culture as described in Example 2. The rHA productivity was estimated by
15 rocket immunoelectrophoresis against HSA standards (25-150gg/mL).
The rHA productivity of DS569 [pAYE329] under these conditions was
calculated to be approximately 45mg/L, while the rHA productivity of
DS 1101 [pAYE329], measured under identical conditions, was calculated
to be 78mg/L.
The plasmid copy number of the hybrid 2 m plasmid of the yeast strains
DS569 [pAYE329] and DS 1101 [pAYE329] was assessed in lOOmL shake
flask culture, as described in Example 3. Quantitation of the hybrid 2 m
plasmid copy number relative to the copy number of the rDNA was
performed by Southern blot analysis with a joint rDNA/HSA cDNA
probe. This showed that the plasmid copy number of the hybrid 2 m
plasmid pAYE329 increased from 48.9 9.2 copies per haploid genome
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
31
in DS569 [pAYE329] to 70.5 15.9 copies per haploid genome in
DS 1101 [pAYE329].
To enable the 'identification of the nature of the original mutation which
was responsible for the increased plasmid copy number and rHA
productivity observed in DS1101 [pAYE329] a partial Sau3A genomic
DNA library was prepared from DS569 high molecular weight genomic
DNA in the centromeric vector YCp50 (30). A new yeast strain DS 1101
ura3 [pAYE329] was prepared from DS1101 [pAYE329] by the method
io described in Example 1. DS1101 ura3 [pAYE329] was transformed to
uracil prototrophy with DNA from the DS569 YCp50 genomic library.
The transformants were assayed for reduced rHA expression by an anti-
HSA antibody dependant plate screening procedure described in
EP431880. One isolate, DS1101 ura3 [pAYE329/pAYE792], was
is identified which had reduced rHA productivity when assessed in lOmL in
shake flask culture. Yeast were inoculated into YNB (Difco) minimal
medium, buffered with sodium phosphate/citrate pH 6.0 and containing
2% w/v glucose, and incubated at 30 C, 200 rpm for 3 days. The rHA
productivity was estimated by rocket immunoelectrophoresis against HSA
20 standards and was shown to be reduced compared to the DS1101 ura3
[pAYE329/YCp50] control, but similar to the DS569 ura3
[pAYE329/YCp50] control. The plasmid copy number of the hybrid 2 m
plasmid of the yeast strains DS569 ura3 [pAYE329/YCp50], DS569 ura3
[pAYE329/pAYE792], DS1101 ura3 [pAYE329/YCp50] and DS1101
25 ura3 [pAYE329/pAYE792] was assessed in lOOmL shake flask culture, as
described in Example 3. Quantitation of the hybrid 2 m plasmid copy
number relative to the copy number of the rDNA was performed by
Southern blot analysis with a joint rDNA/HSA cDNA probe. This
III
CA 02295190 2000-06-27
WO 99/00504 PCT/GB98/01885
32
showed that the plasmid copy number of the hybrid 2pm plasmid
pAYE329 reduced from 59.4 6.0 copies per haploid genome in DS1101
ura3 [pAYE329/YCp50] to 38.3 1.3 copies per haploid genome in
DS1101 ura3 [pAYE329/pAYE7921, but remained unchanged in DS569
ura3 [pAYE329/YCp50] and in DS569 ura3 [pAYE329/pAYE792] at
33.0 5.3 and 27.5 4.5 copies per haploid genome, respectively.
The pAYE792 centromeric plasmid DNA was isolated from strain DS 1101
ura3 [pAYE329/pAYE792] (31) into E. coli and DNA sequenced (Figure
to 9). This revealed that the plasmid pAYE792 contained a contiguous
9.05kb genomic insert from chromosome II of Saccharom_yces cerevisiae
(32) spanning the region incorporating the UBC4, TECI and MISI genes.
Subsequent subcloning of the three individual genes showed that the UBC4
gene was responsible for the reduced rHA productivity and reduced
1s plasmid copy number associated with pAYE792 in the strain DS1101 ura3
[pAYE329/pAYE792).
In order to establish the nature of the mutation introduced into DS 1101 by
the NTG mutagenesis of DS569 the UBC4 gene from DS 1101 was isolated
2o by PCR. Two single stranded oligonucleotide primers (UBC4A and
UBC4B) suitable for the PCR amplification of the 2.lkb UBC4 genomic.
Pstl fragment (Figure 3) were prepared using an ABI 380B DNA
Synthesiser.
25 UBC4A 5'-ACTCCTGCAG TTATTCTTCT GCC-3'
(SEQ ID NO:5)
UBC4B 5'-GTGTACAATA AGCTGCAGTA CTC-3'
(SEQ ID NO:6)
CA 02295190 2006-02-24
WO 99/00504 PCT/C898/01885
33
PCR reactions were performed to amplify the UBC4 gene from high
inolecular weight genomic DNA prepared from DS1101 according to
reference 30. Conditions were as follows: 50ng/mL to 0.5ng/mL DS110
genomic DNA, 2gM of each primer, denature at 94 C for 30 seconds,
anneal to 50 C for 40 seconds, extend at 72 C for 120 seconds for 40
cycles, followed by a 72 C soak for 600 seconds, followed by a 4 C soak,
using a Perkin-Elmer-Cetus Thermal Cycler and a Perkin-Elmer-Cetus
PCR kit employing AmpliTaqTM Thermal Stable DNA Polymerase, total
reaction volume 50 L, according to the manufacturer's instructions. The
amplified 2.1 kb DNA product was purified by TAE agarose gel
electrophoresis by Geneclean III DNA extraction kit (BiolOl Inc., 1070
Joshua Way, Vista, CA 92083, USA) and digested to completion with
Pstl. The plasmid pBST +(Figure 10) was prepared from the phagemid
pBS+ (Stratagene, 11011 North Torrey Pines Road, La Jolla, California
92037, USA) by digesting pBS + with EcoRl and HindIII. The isolated
linearised vector was ligated with a double stranded oligonucleotide linker
with the sequence:
5' -
AGCTCCTAGGCCCGGGCGGCCGCAAGCTTGTCGACGCTAGCTGCAGAAGG
3'-GGATCCGGGCCCGCCGGCGTTCGAACAGCTGCGATCGACGTCTTCC
ATCCAGATCTCGAGGCGCCATCGAT-3'(SEQ ID NO:7)
TAGGTCTAGAGCTCCGCGGTAGCTATTAA-5'(SEQ ID NO: 8)
Plasmid pBST+ was linearised with Pstl and ligated with the Pstl digested
PCR amplified 2.1kb UBC4 DNA product to generate four separate
plasmid isolates, called pDB2258, pDB2259, pDB2260 and pDB2261
(Figures 11-14). The Pstl inserts of all four plasmids (DS1101 derived)
3o and the UBC4 gene isolated from pAYE792 (DS569 derived) were DNA
sequenced. The DNA sequence analysis revealed a mutation within the
CA 02295190 2000-06-27
WO 99/00504 PGT/GB98/01885
34
DS 1101 UBC4 gene. This mutation, a G to an A substitution, was located
in the tenth codon and had the DNA sequence:
DS569 IIBC4 gene: ATG TCT TCT TCT AAA CGT ATT GCT AAA GAA CTA
(SEQ ID N0:9)
Met Ser Ser Ser Lys Arg Ile Ala Lys Glu Leu
(SEQ ID NO:10) . =
DS1101 UBC4 gene: ATG TCT TCT TCT AAA CGT ATT GCT AAA AAA CTA
(SEQ ID NO:11)
Met Ser Ser Ser Lys Arg Ile Ala Lys Lys Leu
(SEQ ID NO:12)
=..,vto The mutation was such that it would change the tenth amino acid from a
glutamic acid to a lysine, denoted as GlulOLys.
This mutant form, or indeed any mutant form, of the UBC4 gene can be
introduced into any strain in which the UBC4 gene has already been
disrupted by URA3, as already described in Example 1, by procedures
similar to those already described in the literature for the replacement of
the endogenous Saccharonzyces cerevisiae UBC4 gene by the
Caenorhabditis elegans ubc-2 gene (36). The yeast strain UB05 (Example
1) was transformed to ura3 (Ura-) with the 2.lkb Pstl fragment from
2o either of the plasmids pDB2258, pDB2259, pDB2260 or pDB2261
(Figures 11-14) and selecting for Ura yeast by resistance to 5-fluoro-
orotic acid (18). Colonies able to grow on this medium were purified,
tested to verify that they were unable to grow in the absence of uracil
supplementation and that the defect could be complemented by
introduction of the URA3 gene by transformation. Removal of the URA3
gene from the UBC4 locus in UB05 and its replacement by the GlulOLys
mutant form of the UBC4 gene was confirmed by Southern Blot.
CA 02295190 2000-06-27
WO 99/00504 PCT/GB98/01885
Example 8: Disruption of the Saccharoinyces cerevisiae UBCS gene
The Saccharomyces cerevisiae UBC5 gene is located on chromosome IV.
The DNA sequence of the UBCS gene is shown in Figure 15 _
5 r
The UBC5 gene was mutated by the process of gene disruption (14) which
deleted the entire UBC5 open reading frame, thereby preventing
production of active Ubc5 protein. This was achieved by first amplifying
by PCR a suitable marker gene (URA3) with mutagenic single stranded
io DNA primers which modified the 5' and 3' ends of the URA3 gene so as
to include DNA sequences identical to regions 5' and 3' to the UBC5 open
reading frame and then transforming a ura3 auxotrophic yeast strain to
uracil prototrophy.
ts Two single stranded oligonucleotide primers (UBC5URA1 and
UBC5URA2) suitable for PCR amplification of the 5' and 3' ends of the
URA3 gene, incorporating UBC5 sequences at the extremes, were
synthesised using an ABI 380B DNA Synthesiser.
20 UBC5URA 1 5'-AGGACTGCTT ATTGACTACC ATCTTGAAAA
GTCATTTTCT GCTCACCACC AGCTTTTCAA
TTCATCTTTT-3' (SEQ ID No :13 )
UBC5URA2 5'-TTGATGTGTG CGCTGAGGAA GGTAAGTCTA
25 CACAATTTAT CCGTTAGCCC AGCTTTTTCT
TTCCAATTTT-3' (SEQ ID No :14 )
CA 02295190 2006-02-24
WO 99/00504 PCT/G898101885
36
PCR reactions were performed to amplify the URA3 gene from the
plasmid YEp24 (15). Conditions were as follows: l g/mL plasmid
YEp24 DNA, 2 M of each primer, denature at 94 C for 30 seconds,
anneal to 45 C for 40 seconds, extend at 72 C for 120 seconds for 20
s cycles, followed by a 72 C soak for 600 seconds, following by-a 4 C soak,
using a Perkin-Elmer-Cetus Thermal Cycler and a Perkin-Elmer-Cetus
PCR kit employing AmpliTaqTM rhermal Stable DNA Polymerase, total
reaction volume 50 L, according to the manufacturer's instructions.
Alternative conditions were, 2ng/mL plasmid YEp24 DNA, 0.1 M of
io each primer, denature at 94 C for 30 seconds, anneal to 55 C for 40
seconds, extend at 72"C for 120 seconds for 30 cycles, followed by a 72 C
soak for 600 seconds, followed by a 4 C soak, using a Perkin-Elmer-Cetus
Thermal Cycler and a Perkin-Elmer-Cetus PCR kit employing AmpliTaqTM
Thermal Stable DNA Polymerase, total reaction volume 50 L, according
is to the manufacturer's instructions. The product, 5'-UBC5-URA3-UBCS-
3', was analysed by gel electrophoresis and was found to be of the
expected size, approximately 1.2kb. The amplified PCR product was
purified using a Promega Wizard PCR DNA purification kit according to
the manufacturer's instructions.
DS569 ura3 [pAYE329] was transformed to uracil prototrophy with the
5'-UBC5-URA3-UBC5-3' PCR product. A Southern blot of digested
genomic DNA of a number of transformants was probed with the UBC5
gene as a 0.5kb M1uI-Asp718 DNA fragment and confirmed the disruption
of the UBC5 gene. The new strain was designated UBI [pAYE329].
In an alternative method to disrupt the UBCS gene portions corresponding
to the 5' and 3' ends of the UBCS gene were cloned by PCR. Two pairs
CA 02295190 2006-02-24
WO 99/00504 PCT/G[398/01885
37
of single stranded oligonucleotide primers suitable for PCR amplification
uf the 5' end of the UBC5 gene (DS 101 and DS 102) and the 3' end of the
UBC5 gene (DS 103 and DS 104), were synthesised using an ABI 380B
DNA Synthesiser.
S
DS 101 5'-TGACGCGGCC GCTCTAGATG TATTGCTAGT
GCTAGTACGG TG-3' (SEQ ID NO : 15)
..,.
DS102 5'-TGACGTCGAC AAGCTTGGAA AATAAAACTC
CAACCATC-3' (SEQ ID NO :16 )
DS 103 5'-TGACAAGCTT GTGTAGACTT ACCTTCCTCA
GCGC-3' (SEQ ID NO :17 )
1s DS104 5'TGACGCTAGC ACGCGTCTGA CTTCTAATCA
GAAGATTATG GG-3' (SEQ ID NO :18 )
PCR reactions were performed to amplify the 5' end of the UBC5 gene.
Conditions were as follows: 1000-1Ong/mL S288C genomic DNA, 2 M
2o DS101 primer, 2 M DS102 primer, denature at 94 C for 30 seconds,
anneal to 37 C for 30 seconds, extend at 72 C for 60 seconds for 30
cycles, followed by a 72 C soak for 600 seconds, following by a 4 C soak,
using a Perkin-Elmer-Cetus Thermal Cycler and a Perkin-Elmer-Cetus.
PCR kit employing AmpliTaqTM Thermal Stable DNA Polymerase, total
25 reaction volume 50 L, according to the manufacturer's instructions. The
product, 5'-UBC5, was analysed by gel electrophoresis and was found to
be of the expected size, 229bp The amplified PCR product was purified
CA 02295190 2006-02-24
WO 99/00504 PCT/GB98/01885
38
using a Promega Wizard PCR DNA purification kit according to the
manufacturer's instructions.
PCR reactions were performed to amplify the 3' end of the UBC5 gene.
Conditions were as follows: 1000-1Ong/mL S288C genomic DNA, 2gM
DS 103 pritner, 2 M DS 104 primer, denature at 94 C for 30 seconds,
anneal to 37 C for 30 seconds, extend at 72 C for 60 seconds for 30
cycles, followed by a 72 C soak for 600 seconds, following by a 4 C soak,
using a Perkin-Elmer-Cetus Thermal Cycler and a Perkin-Elmer-Cetus
to PCR kit employing AmpliTaqTM Tliermal Stable DNA Polymerase, total
reaction volume 50 L, according to the manufacturer's instructions. The
product, 3'-UBC5, was analysed by gel electrophoresis and was found to
be of the expected size, 327bp.
The 5'-UBC5 DNA fragment was digested to completion with NotI and
Sall, phenol/chloroform extracted and cloned into NotI/Sall linearised and
phosphatased pBST+ to generate plasmid pDB2262 (Figure 16). The 3'-
UBC5 DNA fragment was digested to completion with Nhel and HindIII,
phenol/chloroform extracted and cloned into Nhel/HindIIl linearised and
phophatased pBST+ to generate plasmid pDB2264 (Figure 17). The
DNA inserts of pDB2262 and pDB2264 were sequenced to confirm their
identity. Plasmid pDB2264 was digested to completion with HindIIIlNheI
and the 327bp fragment corresponding to the 3' end of UBC5 isolated and
cloned into pDB2262, linearised with HiridIII/NIzeI and phophatased. The
resultant plasmid called pDB2275 contained the 5' and 3' ends of the
UBCS gene, separated by a uiiique HindI1I site (Figure 18). The entire
genomic URA3 gene isolated as a 1.2kb HindIII fragment was cloned into
linearised pDB2275 with HindIll and pliosphatased, gencrating plasmids
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
39
pDB2276 (Figure 19) and pDB2277 (Figure 1) which only differed from
each other by the orientation of the URA3 marker gene.
DS569 ura3 [pAYE329] was transformed to uracil prototrophy with the
5'-UBC5-URA3-UBCS-3' disrupting fragment isolated from either
pDB2276 or pDB2277 as 1.7kb MluI-Xbal fragments. The rHA
productivity of these yeast transformants was assessed in lOmL shake
flask culture. Yeast were inoculated into YNB (Difco) minimal medium,
buffered with sodium phosphate/citrate pH 6.0 and containing 2% w/v
io glucose, and incubated at 30 C, 200 rpm for 3 days. The rHA
productivity was estimated by rocket immunoelectrophoresis against HSA
standards (25-150 g/mL). The rHA productivity of DS569 [pAYE329]
under these conditions was calculated to be approximately 40mg/L, while
the rHA productivity of some of the pDB2276 or pDB2277 transformants
is measured at the same time was increased to a level greater than that of
DS569 [pAYE329], calculated to be approximately 60mg/L (Figure 2).
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
REFERENCES
1. Varshavsky, A. (1992) Cell 69, 725-735.
2. McGarth, J. P. , et al (1991) EMBO J. 10, 227-236.
5 3. Seufert, W. and Jentsch, S. (1990) EMBO J. 9, 543-550.
4. Hinnen, A., et al (1978) P. N.A. S. (USA) 75, 1929.
5. Esser, K., et al (1986) "Plasmids of eukaryotes" Springer-Verlag
KG, Heidelberg, Germany.
6. Wickner, R.B., et al (1986) "Extrachromosomal elements in lower
10 eukaryotes" Plenum Publishing Corp., New York.
7. Murray, J.A.H. (1987) Molecular Microbiology 1, 1-4.
8. Futcher, A.B. (1988) Yeast 4, 27-40.
9. Volkert, F.C., et al (1989) Microbiological Reviews 53, 299-317.
10. Hartley, J.L. and Donelson, J.E. (1980) Nature (Lond) 286, 860-
15 865.
11. Murray, J.A.H., et al (1987) EMBO J. 6 4205-4212.
12. Beggs, J.D. (1981) "Molecular Genetics in Yeast" Alfred Benz on
Symposium 16, 383-395.
13. Maniatis, T., et al (1982) and Sambrook et al (1989) "Molecular
20 Cloning: A Laboratory Manual" Cold Spring Harbor Laboratory,
Cold Spring, New York.
14. Rothstein, R.J. (1983) Metlzods Enzymol. 101, 203-211.
15. Botstein, D., et al (1979) Gene 8, 17-24.
16. Sleep, D., et al (1991) Bio/Technology 9, 183-187.
25 17. Chang, A.C.Y. and Cohen, S.N. (1978) J. Bacteriol. 134,
1141-1156.
18. Boeke, J.D., et al (1987) Methods Enzynzol. 154, 164-175.
19. Sleep, D., et al (1991) Gefze 101, 89-96.
CA 02295190 1999-12-10
WO 99/00504 PCT/GB98/01885
41
20. Rose, A.B. and Broach, J.R. (1990) Methods Enzymol. 185, 234-
279.
21. EP-A-0 431 880.
22. Jentsch, D. (1992) Annu. Rev. Genet. 26, 179-207.
23. Botstein and Shortle (1985) "Strategies and Applications of In Vitro
Mutagenesis" Science 229, 193-210.
24. Winston, F. et al (1983) Methods Enzymol. 101, 211-228.
25. Rose, M., et al (1987) Gene 60, 237-243.
26. Gietz, R. and Sugino, A. (1988) Gene 74, 527-534.
to 27. Mumberg D., et al (1994) Nuc. Acids Res. 22, 5767-5768.
28. Ogden, J.E. et al (1994) Meth. Enz. 231, 374-390.
29. Cook, W. et al (1993) Biochemistry 32, 13809-13817.
30. Rose, M.D. et al (1987) Gene 60, 237-243.
31. Lee, F-J, S. (1992) Biotechniques 12, 677.
32. Feldmann, H, et al (1994) EMBO J. 13, 5795-5809.
33. Worthylake, et al (1998) J. Biol. Chem 273, 6271-6276.
34. Jensen, J.P. et al (1995) J. Biol. Cheni. 270, 30408-30414.
35. Treier, M. et al (1992) EMBO. J. 11, 367-372.
36. Zhen, M. et al (1993) 13, 1371-1377.
2o 37. Girod, P-A. et al (1993) Plant J. 3, 545-552.
38. Damagnez, V. et al (1995) Gene 155, 137-138.
-39. Holm, C. (1982) Cell 29, 585-594.
~ .'f~.
fll
CA 02295190 2000-06-27
42
SEQVENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Delta Biotechnology Limited
(B) STREET: Castle Court, Castle Boulevard
(C) CITY: Nottingham
(E) COUNTRY: UK
(F) POSTAL CODE (ZIP): NG7 1FD
(ii) TITLE OF INVENTION: Improved Protein Expression Strains
(iii) NUMBER OF SEQUENCES: 20
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: BERESKIN & PARR
(B) STREET: 40 King Street West
(C) CITY: Toronto
(D) STATE: Ontario
(E) COUNTRY: Canada
(F) ZIP: M5H 3Y2
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO)
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 2,295,190
(B) FILING DATE: 26-JUN-1998
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Gravelle, Micheline
(B) REGISTRATION NUMBER: 4189
(C) REFERENCE/DOCKET NUMBER: 3167-42
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (416) 364-7311
(B) TELEFAX: (416) 361-1398
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 70 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR primer"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
TTTCATCGTC CAATCCCATA TAAATCTTGC TTCTCTTTTT CAGCTGAGTA AGCTTTTCAA 60
TTCATCTTTT 70
CA 02295190 2000-06-27
43
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 70 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR primer"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
TCTTATTTTT CATCTTAATA AATAATCCAG AGAATAAATC TATCCTGAAA AGCTTTTTCT 60
TTCCAATTTT 70
(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR primer"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
ATAAACAAGC TTCCAAAAAA ACATGATTTC ACTGACTATA GAGTACATAC 50
(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 54 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR PRIMER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
GTAAGGACTT AAGCTTTATA CAGCGTATTT CTTTGTCCAT TCTCTGGCTG TAGC 54
CA 02295190 2000-06-27
44
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR PRIMER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
ACTCCTGCAG TTATTCTTCT GCC 23
(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR PRIMER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
GTGTACAATA AGCTGCAGTA CTC 23
(2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 75 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "OLIGONUCLEOTIDE LINKER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
AGCTCCTAGG CCCGGGCGGC CGCAAGCTTG TCGACGCTAG CTGCAGAAGG ATCCAGATCT 60
CGAGGCGCCA TCGAT 75
CA 02295190 2000-06-27
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 75 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "OLIGONUCLEOTIDE LINKER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
AATTATCGAT GGCGCCTCGA GATCTGGATC CTTCTGCAGC TAGCGTCGAC AAGCTTGCGG 60
CCGCCCGGGC CTAGG 75
(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
ATGTCTTCTT CTAAACGTAT TGCTAAAGAA CTA 33
(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
Met Ser Ser Ser Lys Arg Ile Ala Lys Glu Leu
1 5 10
CA 02295190 2000-06-27
46
(2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
ATGTCTTCTT CTAAACGTAT TGCTAAAAAA CTA 33
(2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
Met Ser Ser Ser Lys Arg Ile Ala Lys Lys Leu
1 5 10
(2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 70 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR PRIMER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
AGGACTGCTT ATTGACTACC ATCTTGAAAA GTCATTTTCT GCTCACCACC AGCTTTTCAA 60
TTCATCTTTT 70
CA 02295190 2000-06-27
47
(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 70 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR PRIMER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
TTGATGTGTG CGCTGAGGAA GGTAAGTCTA CACAATTTAT CCGTTAGCCC AGCTTTTTCT 60
TTCCAATTTT 70
(2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR PRIMER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
TGACGCGGCC GCTCTAGATG TATTGCTAGT GCTAGTACGG TG 42
(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR PRIMER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
TGACGTCGAC AAGCTTGGAA AATAAAACTC CAACCATC 38
CA 02295190 2000-06-27
48
(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR PRIMER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
TGACAAGCTT GTGTAGACTT ACCTTCCTCA GCGC 34
(2) INFORMATION FOR SEQ ID NO: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "PCR PRIMER"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
TGACGCTAGC ACGCGTCTGA CTTCTAATCA GAAGATTATG GG 42
(2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2072 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:
CTGCAGTACT CTTTTGATTC TGTAGGAAAC CAGCGAAGAA CGTACTCTTG CCTGAAGAGA 60
AGTTTTTTTT ATTTATTTAT ATTTTGTTCT GGAAGCTCTT TACAGAATGG AGTAGGAAAA 120
CA 02295190 2000-06-27
. ,
49
TATATAGAGA GGAAAAGCGA AATCGTTACG AGAATAAATA ATCAAGAAAA GAAACTTGAA 180
CTTGGCTTTT CCAAAACAAC AGAAGTAGCG TTAATTTACT TTCACCGTAA AATTCAACTC 240
TTTAAATATA GTCCACTTAG TAAATTCTTG CCAATTTGCA TGATAAATTC GAACCCATTC 300
CTCAAAATAA AGGGTCCTCA TACATTCCAT GGAAAGAAAG TTTTCTTGAA CATTAAGAAT 360
AAAAAGGCAA AAAAGAAAAA AAAAAGCACA GCTACTGTTT TAGTCAACAT TCCTTTCTCA 420
CTGGAATGCA CAAGGTGTCA TTCCTGAACA AGGGTAACTG CACTATTCAT ATGTCCACCT 480
TATGACTTCA TAAAAAGTTT GACAATAAGT AGTCTTACGT GATAAGAAAT GATGTAACAT 540
AAGGCTAATG TCCTTATTCC AAAGTATCTC ATTTATACAA TAAACAAAAC TGATCTTACC 600
GCCTATCCTC CTCTCCGCAC TAATCAATTG TTATAGTTTT TCTCGAAGCG AGGATCAAAT 660
GGCCGAGCAA CAGGAAAAGG AGTACCGGCG GTCACATGGT CTGCGAGATT TTTCCCGCTG 720
CGGAAAAACC TGGCAACAGC TCACCTTGAA AGGCCTTGGC CTGTATTTTT CTTTTTTCTT 780
CATCCTTCTT TCTTTTTCTT TATTCTTATT TTTCATCTTA ATAAATAATC CAGAGAATAA 840
ATCTATCCTG AAAAAAAATA AAGTAAAGAA GCCAGGAAAA TCACTATCGC CACAAGTAAA 900
TAAATTTCAC TGACTATAGA GTACATACAT AAACAAGCAT CCAAAAAAAC ATGTCTTCTT 960
CTAAACGTAT TGCTAAAGAA CTAAGTGATC TAGAAAGGTA TGTCTAAAGT TATGGCCACG 1020
TTTCAAATGC GTGCTTTTTT TTTAAAACTT ATGCTCTTAT TTACTAACAA AATCAACATG 1080
CTATTGAACT AGAGATCCAC CTACTTCATG TTCAGCCGGT CCAGTCGGCG ATGATCTATA 1140
TCACTGGCAA GCATCCATCA TGGGACCTGC CGATTCCCCA TATGCCGGCG GTGTTTTCTT 1200
CTTGTCTATC CATTTCCCAA CCGACTACCC ATTCAAGCCA CCAAAGATCT CCTTCACAAC 1260
CAAGATATAT CATCCAAATA TCAATGCCAA TGGTAACATC TGTCTGGACA TCCTAAAGGA 1320
TCAATGGTCT CCAGCTCTAA CTCTATCGAA GGTCCTATTA TCCATCTGTT CTTTGTTAAC 1380
AGACGCTAAT CCTGACGATC CTTTAGTACC AGAAATCGCT CATATCTACA AGACTGACAG 1440
ACCCAAGTAC GAAGCTACAG CCAGAGAATG GACAAAGAAA TACGCTGTAT AAACAGAAGT 1500
CCTTACTCAG CTGAAAAAGA GAAGCAAGAT TTATATGGGA TTGGACGATG AAAAGAATAT 1560
TAGATACAAT GTATTTAAGA AAGAATACAA TAAAATATAT GTATATTCTA TCTCTAATAA 1620
CATAGATTTA CTGATATAAG ATATAAGACT ATTGTTGGCA ACAGTACAGG GGAACCTTTT 1680
TTTTTTTTTC CAAACAACTC GAATCGTAAA CCTTAATTTA ATTTATTCAG GGGAGATTCA 1740
TGAACATTTT TTTCCTCGAA CAGTATGGAG AATTTTTGCT TAGTTACATG CACGCAAGCG 1800
CGGGTATACC CGCATATATT TCAGTTGTGG TTCATAATTT GACCTAACTT GTCGAGGGAG 1860
CGTCAACGTT AACCGTACCT TTTTCATTTC TAGTCTATCT GTAGGTTAAT TACTATTGTC 1920
ATTAACATCA TTTCTGGGGT GAAGCCTATT TAAATTTTTG AAGTTCAACG CATAGCTAGT 1980
ATATGTAATC AACGATCAAT GACTGGTTCT CTGTTTGGCA AAAATTCTGA GGAGCATTAC 2040
ACTGTACTAA GGAGGCAGAA GAATAACTGC AG 2072
(2) INFORMATION FOR SEQ ID NO: 20:
CA 02295190 2000-06-27
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1206 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:
AGATCTGCTA TTGCATGTGG TGAAAGTTAT ACCAACATTT TTGCTTATAT GAAATCATCT 60
GCAACAACCA ATTGGATAAG GATAGATTTC TCAAATATAT TAAATTATGT CTTGGTTTAC 120
TTACACAGAA AGTCCCAAAG TACAGATGAA TTATACTAGG GTTGTGTTCA TTGTTCCATG 180
AGAGGCTGTA CTTTTTGCCT ACTTATTTTG GTACTCATTC ATTAGGCTCA TAAACCGATT 240
TTTCTTATAT TGTGCGTAAT TCAATTAGAT ATCTAGATGT ATTGCTAGTG CTAGTACGGT 300
GTAAACTCTC GTAGCAAGCG TTTTGAAGCA TGGCTGTGGT GGAGGTAGTT GCCACTGCGA 360
GCGGGTAATA AAGCGGCTGC CGCCTTACTC ATTTGTACCA AAGATAGCCG ACCCAAAATT 420
ATAAAAAATA ATTGTATCCC GGATTTTAAT AGATGGTTGG AGTTTTATTT TCCAAGGTCA 480
GGACTGCTTA TTGACTACCA TCTTGAAAAG TCATTTTCTG CTCACCACCC TCAACTAAAC 540
TAAAAATGTC TTCCTCCAAG CGTATTGCCA AGGAATTAAG TGATTTAGGG AGGTATGTTA 600
AAAATAAAAT AATGATTTTT CTTGATCTGT AAAGAAAAAG GATTACTAAC ATGAGTTTCT 660
TTTTTGAACT TTTTTCCGAA GAGATCCTCC TGCTTCATGT TCAGCAGGAC CTGTAGGGGA 720
TGACCTGTAT CATTGGCAAG CCTCTATTAT GGGTCCTTCA GACTCACCCT ACGCTGGTGG 780
CGTTTTCTTT TTGTCTATTC ACTTTCCAAC TGATTATCCA TTCAAGCCAC CGAAGGTAAA 840
CTTTACGACC AAAATTTATC ATCCGAATAT TAATTCGAGT GGTAATATCT GCCTTGATAT 900
TTTAAAGGAC CAGTGGTCAC CGGCGCTAAC CCTTTCAAAA GTTTTGTTGT CTATTTGCTC 960
TCTTTTAACA GATGCTAATC CCGACGATCC TTTGGTCCCT GAAATTGCTC AAATCTACAA 1020
GACAGATAAG GCTAAGTATG AAGCCACCGC TAAGGAGTGG ACTAAAAAAT ATGCTGTTTG 1080
ATTAATTTGG GCTAACGGAT AAATTGTGTA GACTTACCTT CCTCAGCGCA CACATCAATA 1140
TATTATATAT TCTTTACGTA TACAAACACG CAAATTCTTA TAGGTATAGC GATATTAGTT 1200
TGATCA 1206
